Skip to main content

Development of prophylactic and therapeutic vaccines optimised for cellular processing and presentation to t lymphocytes and targeted to professional antigen presenting cells (protarvac)

Objective

Vaccines eliciting T cell immunity are likely to be important for protection against diseases such as infection by HIV, HCV or malaria parasites. Current concepts of peptide or protein fragment vaccination do not consider intracellular antigen processing in epitome selection and design of poly-epitome strings. We propose to study proteolysis by immune- and housekeeping protease, and bylysosomal proteases, so as to identify novel epitomes by an enhanced "reverse immunology" approach, to determine distinct epitome sets suitable for preventive and therapeutic vaccines, and to design linkers for optimal intracellular epitoperelease and transport. T cell vaccines for HIV, HCV and malaria will be designed and tested with healthy donor or patient lymphocytes and in a marine malaria model.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
161,Rue De Sfvres 161
75743 Paris
France

Participants (3)

FOUNDATION "ANDREA CESALPINO"
Italy
Address
Viale Del Policlinico 155
00161 Roma
M-SCAN LTD.
United Kingdom
Address
Silwood Park, Sunninghill
SL5 7PZ Ascot
MRC National Institute for Medical Research
United Kingdom
Address
The Ridgeway Mill Hil
NW7 1AA London